50 patents
Utility
Tetrahydropyridopyrimidines and Related Analogs for Inhibiting Yap/taz-tead
18 Jan 24
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis.
Bart VANDERHOYDONCK, Arnaud MARCHAND, Wim SMETS, Aurélie CANDI, Matthias VERSELE
Filed: 2 Feb 23
Utility
Treatments with nirogacestat
16 Jan 24
The present disclosure relates to improved methods of treatment with nirogacestat.
Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
Filed: 19 May 23
Utility
Non-linear Dosing of Mirdametinib
4 Jan 24
The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
Uchenna H. ILOEJE, Abraham J. LANGSETH, Todd SHEARER
Filed: 2 Aug 23
Utility
Chlorinated tetralin compounds and pharmaceutical compositions
19 Dec 23
The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
Kristin Patterson, Mark Hatcher
Filed: 17 Apr 23
Utility
Mirdametinib treatment
12 Dec 23
The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
Filed: 20 Mar 23
Utility
Dihydroquinazolinones and Related Analogs for Inhibiting Yap/taz-tead
7 Dec 23
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis.
Bart VANDERHOYDONCK, Arnaud MARCHAND, Aurélie CANDI, Matthias VERSELE
Filed: 24 Feb 23
Utility
Treatments with Nirogacestat
23 Nov 23
The present disclosure relates to improved methods of treatment with nirogacestat.
Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
Filed: 19 May 23
Utility
Treatments with Nirogacestat
23 Nov 23
The present disclosure relates to improved methods of treatment with nirogacestat.
Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
Filed: 19 May 23
Utility
Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib
21 Nov 23
The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
Filed: 16 Mar 23
Utility
Non-linear dosing of mirdametinib
7 Nov 23
The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
Filed: 16 Mar 23
Utility
Mirdametinib treatment
7 Nov 23
The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
Filed: 16 Mar 23
Utility
Chlorinated tetralin compounds and pharmaceutical compositions
7 Nov 23
The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
Kristin Patterson, Mark Hatcher
Filed: 17 Apr 23
Utility
Dispersible Formulations of N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE and Uses Thereof
19 Oct 23
The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.
Kristin PATTERSON, Jiping LIU
Filed: 9 Jan 23
Utility
Mirdametinib Treatment
12 Oct 23
The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF 1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
Uchenna H. Iloeje, Abraham J. Langseth, Todd Shearer
Filed: 16 Mar 23
Utility
Mirdametinib Treatment
12 Oct 23
The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
Uchenna H. Iloeje, Abraham J. Langseth, Todd Shearer
Filed: 14 Jun 23
Utility
Fluorinated phenylamino compounds and pharmaceutical compositions
10 Oct 23
The present disclosure relates to fluorinated phenylamino compounds, their pharmaceutical compositions, and methods for treating one or more tumors or cancers selected from the group consisting of plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), cutaneous neurofibromas (cNF), pancreatic ductal adenocarcinoma (PDAC), high grade glioma (HGG), low grade ovarian cancer, tuberous sclerosis (TSC), Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain, comprising administering to a patient in need thereof, those pharmaceutical compositions.
Kristin Patterson, Piero L Ruggiero
Filed: 16 Mar 23
Utility
Chlorinated Tetralin Compounds and Pharmaceutical Compositions
5 Oct 23
The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
Kristin PATTERSON, Mark HATCHER
Filed: 17 Apr 23
Utility
Synthesis of Nirogacestat
5 Oct 23
The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (“nirogacestat”).
Kristin PATTERSON, Mark HATCHER
Filed: 20 Apr 23
Utility
Non-linear Dosing of Mirdametinib
21 Sep 23
The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
Uchenna H. Iloeje, Abraham J. Langseth, Todd Shearer
Filed: 16 Mar 23
Utility
Treatment of cutaneous neurofibromas with Mirdametinib
21 Sep 23
The present disclosure relates to methods for treating cutaneous neurofibromas (cNF) comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
Uchenna H. Iloeje, Abraham J. Langseth
Filed: 16 Mar 23